Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Peter Hirth et al.|Nature|2010Cited by 1.8k
Network modeling links breast cancer susceptibility and centrosome dysfunctionMiguel Ángel Pujana, Marc Vidal, Jing-Dong Han et al.|Nature Genetics|2007Cited by 634
Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian CancerTimothy R. Rebbeck, Saundra S. Buys, Nandita Mitra et al.|JAMA|2015Cited by 507
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival PatternsA. Rose Brannon, W. Kimryn Rathmell, A. Arreola et al.|Genes & Cancer|2010Cited by 332
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriersKara N. Maxwell, Katherine L. Nathanson|Nature Communications|2017Cited by 308